Chugai And Dainippon Sumitomo To Start Cancer Vaccine Trial In Japan
This article was originally published in PharmAsia News
Executive Summary
Chugai and Dainippon Sumitomo will conduct a joint Phase I/II clinical study of cancer vaccine WT4869 for patients with myelodysplastic syndromes in Japan